Cadila Healthcare (BOM: 532321) is among the leading players in India which focuses on bringing in-house developed innovative therapies for patients. Cadila Healthcare has developed a diversified COVID-19 portfolio among the Indian players through in-house development and licensing opportunities.
In line with this, the COVID-19 situation has put Cadila Healthcare at the forefront of innovation in India, says GlobalData, a data analytics and research company.
According to GlobalData’s ‘Pharmaceutical Intelligence Center’ (as of May 27, 2021), Cadila Healthcare’s COVID-19 portfolio includes one repurposed marketed drug and ‘seven in-house’ candidates in the pipeline, including two in Phase III, one each in Phase II and Phase I and three candidates in preclinical development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze